Cognition Therapeutics (CGTX) Earnings Analysis

Cognition Therapeutics (CGTX) next reports earnings on 2026-08-06, consensus EPS -0.06 USD. Last quarter (2026-05-07) it beat with EPS -0.05 USD vs -0.06 USD est (+16.7%). It has beaten estimates in 4/6 recent quarters (67%). Trailing P/E -3.67.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does CGTX next report earnings?

Next earnings date2026-08-06
Consensus EPS estimate-0.06 USD
Revenue estimate0.01B

CGTX earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-07-0.05 USD-0.06 USD+16.7%Beat
2026-03-26-0.02 USD-0.06 USD+66.7%Beat
2025-11-06-0.06 USD-0.07 USD+14.3%Beat
2025-08-07-0.11 USD-0.12 USD+8.3%Beat
2025-03-20-0.17 USD-0.16 USD-6.3%Miss
2024-11-13-0.25 USD-0.24 USD-4.2%Miss

Beat rate: 4/6 (67%) over reported quarters with consensus data.

CGTX valuation and analyst view

Trailing P/E-3.67
Trailing EPS-0.21949 USD
Price / book2.87
Dividend yield0.00%
Market cap0.07B
Analyst consensusBuy (6 buy / 1 hold / 0 sell)
Avg price target3 USD

Related research pages

Frequently asked questions

When is Cognition Therapeutics (CGTX)'s next earnings date?

Cognition Therapeutics is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.06 USD and revenue estimate of 0.01B.

Did CGTX beat earnings last quarter?

In its 2026-05-07 report, CGTX posted EPS of -0.05 USD versus a -0.06 USD estimate — a beat of 16.7%.

What is CGTX's earnings track record?

Over the last 6 reported quarters with consensus data, CGTX beat estimates 4 times (67%).

What is CGTX's current P/E ratio and EPS?

CGTX trades at a trailing P/E of -3.67 on trailing EPS of -0.21949447027425192 USD.

What do analysts rate CGTX?

Analyst consensus is "Buy" across 7 ratings (0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 3 USD.